Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 20 Jan 2017 Planned End Date changed from 1 Sep 2015 to 1 Apr 2017.
- 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
- 06 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Mar 2015, as reported by ClinicalTrials.gov record